Gelesis Holdings, Inc. (GLSHQ) Stock

About Gelesis Holdings, Inc.

Gelesis Holdings, Inc. operated as a commercial-stage biotherapeutics company, concentrating on the development of biomimetic solutions. Its core mission revolved around addressing the root causes of obesity and various chronic gastrointestinal ailments. Among its offerings was PLENITY, an orally administered, non-stimulant, and non-systemic product designed to assist with weight management. The company's pipeline also included several other promising developments: GS200, targeting weight reduction for individuals with prediabetes and type 2 diabetes; and GS500, intended for the treatment of functional constipation. Furthermore, Gelesis had a pre-clinical stage product, GS300, in development for conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Founded in Boston, Massachusetts, in 2006, the company established its headquarters there. Regrettably, on October 30, 2023, Gelesis Holdings, Inc., alongside its affiliates, formally initiated voluntary Chapter 7 liquidation proceedings in the U.S. Bankruptcy Court for the District of Delaware.

Gelesis Holdings, Inc. (GLSHQ) stock trades at $0.00 with a market capitalization of $7334. The stock is valued at a price-to-earnings (P/E) ratio of -0.20, price-to-book of -0.44, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Gelesis Holdings, Inc. generates a return on equity (ROE) of 228.00% — well above the market average, a sign of a high-quality business, return on capital employed of -231.39%, an operating margin of -902.98%, a net profit margin of -219.23%.

Official website: www.gelesis.com